Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Employees - 54,
CEO - Mr. Ilan Danieli,
Sector - Healthcare,
Country - US,
Market Cap - 9.92M
Altman ZScore(max is 10): -7.03, Piotroski Score(max is 10): 5, Working Capital: $-820000, Total Assets: $16996000, Retained Earnings: $-102440000, EBIT: -4215999, Total Liabilities: $4902000, Revenue: $17922000
- Current Price $6.60 - Analyst Target Price $19.00| Ticker | PRPO |
| Index | - |
| Curent Price | 6.60 |
| Change | -1.94% |
| Market Cap | 9.92M |
| Average Volume | 12.68K |
| Income | -4.29M |
| Sales | 18.53M |
| Book Value/Share | 8.10 |
| Cash/Share | 0.92 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 60 |
| Moving Avg 20days | 14.65% |
| Moving Avg 50days | -2.50% |
| Moving Avg 200days | 5.87% |
| Shares Outstanding | 1.49M |
| Earnings Date | Mar 31 AMC |
| Inst. Ownership | 4.86% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 0.54 |
| Price/Book | 0.82 |
| Price/Cash | 7.14 |
| Price/FCF | 45.11 |
| Quick Ratio | 0.64 |
| Current Ratio | 0.81 |
| Debt/Equity | 0.10 |
| Return on Assets | -24.45% |
| Return on Equity | -32.35% |
| Return on Investment | -33.71% |
| Gross Margin | 35.16% |
| Ops Margin | -22.75% |
| Profit Margin | -23.15% |
| RSI | 53.62 |
| BETA(β) | 1.09 |
| From 52week Low | 69.22% |
| From 52week High | -38.57% |
| EPS | -2.96 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | 42.48% |
| Sales past 5 Year | 45.97% |
| EPS Y/Y | 39.43% |
| Sales Y/Y | 21.95% |
| EPS Q/Q | -137.52% |
| Sales Q/Q | 25.90% |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.97 |
| Perf Week | 12.24% |
| Perf Month | -2.52% |
| Perf Quarter | 2.12% |
| Perf Year | -2.02% |
| Perf YTD | 19.13% |
| Target Price | 19.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer